Observational studyOrphanet journal of rare diseases2025
Cerebrovascular involvement in hereditary spherocytosis: observational cohort and case-control MRI study.
Observational study in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Moyamoya syndrome associated with hereditary spherocytosis: pathogenesis, management, and an illustrative case with rapid radiological progression.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundAnecdotal Literature regarding hereditary spherocytosis, a rare hemolytic anemia, points to an early cerebrovascular involvement that would imply early strict patients’ monitoring and management. However, this issue is under-investigated.
methodsClinical history regarding cerebrovascular events in the young ( < 55 years) was investigated in a referral Center for hereditary spherocytosis (190 patients; mean-age 23.5 ± 17.4 years; range 1–77; 93 females). By means of 3T-MR scanner, intracranial artery stenoses, aneurysms, brain infarctions, vascular-like white matter lesions and signs of sinus thrombosis were searched in 69 adult patients (mean-age 36.5 ± 16.3 years, range 14–76, 38 females) and in 56 healthy subjects (mean-age 34 ± 10.8 years, range 17–66, 36 females). Laboratory and clinical data, including splenectomy, were collated.
resultsAmong patients no cerebrovascular events occurred before the age of 55, while among their first-degree relatives, sudden death of unknown cause occurred in three subjects, two of them not affected by hereditary spherocytosis. In the MR-subgroup, moya-moya or even intracranial stenoses were not observed, while intracranial aneurysm (11.6% vs 8.9%), gray matter infarction (one patient), previous venous thrombosis (one patient) and white matter lesion (49.3% vs 50%) prevalence rates did not differ significantly between patients and controls. White matter changes did not differ also in terms of number or size and were not associated with laboratory or clinical findings.
conclusionsIn spite of an evocative case-report-based Literature, early cerebrovascular involvement in hereditary spherocytosis does not seem to differ significantly from the general population. A strict clinical and MR monitoring in neurological asymptomatic patients seems therefore not recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.